<DOC>
	<DOCNO>NCT00730457</DOCNO>
	<brief_summary>Is VAX125 safe dos range 0.1 8 ug deliver i.m . single dose regimen Is VAX125 able induce post-vaccination serum HAI antibody response healthy adult influenza A virus H1 HA .</brief_summary>
	<brief_title>Phase 1 Safety Immunogenicity Study Healthy Adults VAX125 , Recombinant HA-flagellin Influenza Vaccine</brief_title>
	<detailed_description>Part I : Intramuscular ( i.m . ) vaccination single dose 0.1 µg , 0.3 µg , 1 µg , 2 µg , 3 µg , 5 µg 8 µg STF2.HA1 ( SI ) ( VAX125 ) give Day 0 Part II : Intramuscular ( i.m . ) vaccination single dose placebo one two dose level STF2.HA1 ( SI ) ( VAX125 ) ( optimum dose level determine safety immunogenicity data Part I study ) give Day 0 Part I Primary : To assess safety , reactogenicity , tolerability VAX125 vaccine deliver i.m . single dose regimen dose level 0.1 µg , 0.3 µg , 1 µg , 2 µg , 3 µg , 5 µg , 8 µg healthy adult 18 - 49 year age , inclusive . Secondary : To assess immunogenicity VAX125 vaccine deliver i.m . single dose regimen dose level 0.1 µg , 0.3 µg , 1 µg , 2 µg , 3 µg , 5 µg , 8 µg , induce post-vaccination serum HAI antibody response healthy adult influenza A virus H1 HA . Part II Primary : To assess safety , reactogenicity , tolerability single dose VAX125 vaccine deliver i.m . one two dose level compare placebo , ( optimum dose level determine safety immunogenicity data Part I study ) , healthy adult 18- 49 year age , inclusive . Secondary : To assess immunogenicity single dose VAX125 vaccine deliver i.m . one two dose level compare placebo ( optimum dose level determine safety immunogenicity data Part I study ) induce post-vaccination serum HAI antibody response healthy adult influenza A virus H1 HA antigen .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 49 year inclusive Give write informed consent participate . Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination Females willing use another reliable form contraception approve Investigator negative urine pregnancy test within 24 hour precede receipt vaccination Comprehension study requirement , express availability require study period , ability attend schedule visit . Presence significant uncontrolled medical psychiatric illness ( acute chronic ) . This include institution new medical surgical treatment , significant dose alteration uncontrolled symptom drug toxicity within 3 month screen reconfirm Day 0 prior vaccination . Positive serology HIV1 HIV2 , HBsAg HCV antibody . Cancer , treatment cancer , within 3 year . ( Persons history cancer diseasefree without treatment 3 year eligible ) , exclude basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) allow , unless vaccination site . Impaired immune responsiveness ( cause ) , include diabetes mellitus . Documented influenza infection positive culture 6 month prior screen . Presently receive history receive medication treatment affect immune system allergy shot , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) past 6 month prior screen . Inhaled topical corticosteroid allow . Receipt plan administration nonstudy vaccine within 30 day prior vaccination study , include license influenza vaccine . Immunization emergency basis Tetanus Toxoid Adsorbed adult use ( Td Tdap ) 8 day least 8 day dose study vaccine allow . Administration study vaccine injection delay nonstudy vaccine administer give soon acceptable , describe , provide vaccine administer within two week prior study enrollment . History anaphylactic type reaction inject vaccine . History drug chemical abuse year study . Receipt investigational product nonregistered drug within 30 day prior vaccination currently enrol investigational drug study intend enroll study within ensue study period . Receipt blood blood product 8 week prior vaccination plan administration study period . Donation blood blood product within 8 week prior vaccination time study . Acute disease within 72 hour prior vaccination , define presence moderate severe illness ( determined investigator medical history physical examination ; example , require absence work ) without fever , fever &gt; 37.9ºC orally . Study vaccine administer person minor illness , diarrhea , mild upper respiratory tract infection without lowgrade febrile illness . Vaccination delay subject recover . Any condition , opinion investigator , might interfere study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>influenza</keyword>
	<keyword>recombinant</keyword>
	<keyword>hemagglutinin</keyword>
	<keyword>vaccine</keyword>
</DOC>